BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421-431. [PMID: 29193226 DOI: 10.1111/apt.14428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
Number Citing Articles
1 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
2 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 El Kassas M, Hegazy OM, Salah EM. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations. World J Hepatol 2020; 12(10): 841-849 [PMID: 33200021 DOI: 10.4254/wjh.v12.i10.841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Attia D, El Saeed K, Elakel W, El Baz T, Omar A, Yosry A, Elsayed MH, Said M, El Raziky M, Anees M. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment Pharmacol Ther. 2018;47:1296-1305. [PMID: 29504152 DOI: 10.1111/apt.14538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
5 El Raziky M, Hamdy S, Hamada Y, Abdelaziz NM, Hassany M, Doss W, Zakaria Z. Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00174-3] [Reference Citation Analysis]
6 Shousha HI, Saad Y, Saleh DA, Dabes H, Alserafy M, ElShazly Y, Said M. Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2020;32:1017-22. [PMID: 31789947 DOI: 10.1097/MEG.0000000000001612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Abouelasrar Salama S, Gouwy M, De Zutter A, Pörtner N, Vanbrabant L, Berghmans N, De Buck M, Struyf S, Van Damme J. Induction of Chemokines by Hepatitis C Virus Proteins: Synergy of the Core Protein with Interleukin-1β and Interferon-γ in Liver Bystander Cells. J Interferon Cytokine Res 2020;40:195-206. [PMID: 32031878 DOI: 10.1089/jir.2019.0115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, Elfayomy M, Abdel-Ghafar TS, Abdelkareem M, Sabry A, Fekry M, Shebl N, Rewisha E, Waked I. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis 2018;75:109-14. [PMID: 30077791 DOI: 10.1016/j.ijid.2018.07.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
9 Tabll A, El Shenawy R, Elsharkawy H, Mohamed FZ. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients. Hum Antibodies 2019;27:265-73. [PMID: 31127759 DOI: 10.3233/HAB-190381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ahmed HR, Waly NGFM, Abd El-Baky RM, Yahia R, Hetta HF, Elsayed AM, Ibrahem RA. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS One 2021;16:e0249770. [PMID: 33857212 DOI: 10.1371/journal.pone.0249770] [Reference Citation Analysis]
11 Yousif MM, Ahmed H, Elsadek HM, Shendi AM, Gouda TM, Elsayed IA, Gendia MA, Magdy MM, Lbrahim NF, Sadek AMEM, Zaki AM, Shafeik H, Zahran MH. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies. J Viral Hepat 2020;27:1190-201. [PMID: 32564500 DOI: 10.1111/jvh.13349] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Abd El-wahab EW, Ayoub HA, Shorbila AA, Mikheal A, Fadl M, Kotkat AM. Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. Clinical Epidemiology and Global Health 2020;8:1177-88. [DOI: 10.1016/j.cegh.2020.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther 2018;47:1690-8. [PMID: 29665069 DOI: 10.1111/apt.14647] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
14 Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep 2018;8:13699. [PMID: 30209349 DOI: 10.1038/s41598-018-32060-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
15 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouad MHA, Salama MM, Naguib GG, Eltabbakh MM, Sherief AF, Abd-Elsalam S. Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. Int J Hepatol 2018;2018:9616234. [PMID: 29755792 DOI: 10.1155/2018/9616234] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
17 El Kassas M, Salah E, Gad A, Hosny A. Improvement of sexual dysfunction in patients after treatment of hepatitis C virus using directly acting antivirals. Curr Med Res Opin 2021;37:967-72. [PMID: 33688780 DOI: 10.1080/03007995.2021.1901677] [Reference Citation Analysis]
18 Said EM, Abdulaziz BA, El Kassas M, El Attar IH, Emadeldeen M, Abd-Elsalam SM. High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Arch Virol 2020;165:1633-9. [PMID: 32356185 DOI: 10.1007/s00705-020-04639-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
20 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
21 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kanda T, Matsuoka S, Moriyama M. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. Hepatol Int 2018;12:291-3. [PMID: 29992512 DOI: 10.1007/s12072-018-9883-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Mushtaq S, Mansoor A, Umar M, Khan A, Siddiqi S, Manzoor S. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol 2020. [PMID: 32129507 DOI: 10.1002/jmv.25745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Ibrahim Mohammed Ebid AH, Ashraf Ahmed O, Hassan Agwa S, Mohamed Abdel-Motaleb S, Mohamed Elsawy A, Hagag RS. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients. J Clin Pharm Ther 2020;45:539-46. [PMID: 31889322 DOI: 10.1111/jcpt.13104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Elbaz T, Abdo M, Omar H, Hassan EA, Zaghloul AM, Abdel-Samiee M, Moustafa A, Qawzae A, Gamil M, Esmat G. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. J Med Virol 2019;91:272-7. [PMID: 30138531 DOI: 10.1002/jmv.25287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
26 Mekky MA, Sayed HI, Abdelmalek MO, Saleh MA, Osman OA, Osman HA, Morsy KH, Hetta HF. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study. Infect Drug Resist. 2019;12:273-279. [PMID: 30774394 DOI: 10.2147/idr.s181638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
27 Ma W, Soliman AS, Anwar WA, Hablas A, El Din TB, Ramadan M, Seifeldin IA, Wilson ML. Forecasted impacts of a sofosbuvir-based national hepatitis C treatment programme on Egypt's hepatocellular cancer epidemic: simulation of alternatives. BMJ Glob Health 2018;3:e000572. [PMID: 29707244 DOI: 10.1136/bmjgh-2017-000572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
29 Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00126-8] [Reference Citation Analysis]
30 El Kassas M, Funk AL, Abd El Latif Y, Vasiliu A, Sherief A, Shimakawa Y, Youssef N, El Tahan A, Elbadry M, Farid AM, El Shazly Y, Doss W, Esmat G, Fontanet A. Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt. Aliment Pharmacol Ther 2018;47:1564-6. [PMID: 29878419 DOI: 10.1111/apt.14628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients. Infect Disord Drug Targets 2020;20:43-8. [PMID: 30009715 DOI: 10.2174/1871526518666180716141806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kamhawy A, Ahmed Said ZN, Abdelhamid SE, El-Sayed M, Eletreby R, Garem HE, El Kassas M, Esmat G. Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals. Arab J Gastroenterol 2021;22:158-63. [PMID: 33820724 DOI: 10.1016/j.ajg.2021.03.001] [Reference Citation Analysis]
33 Perazzo H, Castro R, Luz PM, Banholi M, Goldenzon RV, Cardoso SW, Grinsztejn B, Veloso VG. Effectiveness of generic direct-acting agents for the treatment of hepatitis C: systematic review and meta-analysis. Bull World Health Organ 2020;98:188-197K. [PMID: 32132753 DOI: 10.2471/BLT.19.231522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Lédinghen V, Lusivika‐nzinga C, Bronowicki J, Zoulim F, Larrey D, Metivier S, Tran A, Marcellin P, Samuel D, Chazouillères O, Chevaliez S, Dorival C, Fontaine H, Pawlotsky J, Carrat F, Pol S; The AFEF/ANRS Study Group. Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort. J Viral Hepat 2020;27:964-73. [DOI: 10.1111/jvh.13321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hashem MB, Badary HA, Mahfouz NA, Adel S, Alboraie M, AbdAllah M, AlAkel W, Saeed R, Ammar I, Abdel-Razek W, Hassany M, Esmat G. Evaluation of factors affecting patients' refusal of HCV treatment in a cohort of Egyptian patients. J Public Health (Oxf) 2021:fdab363. [PMID: 34651189 DOI: 10.1093/pubmed/fdab363] [Reference Citation Analysis]
36 Abdelaty LN, Elnaggar AA, Said AA, Hussein RRS. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Curr Drug Saf 2020;15:53-60. [PMID: 31573893 DOI: 10.2174/1574886314666191001151314] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Abdelaziz H, Omar H, Khalil M, Cordie A, Mohamed R, AbdAllah M, Abdel Maksoud MH, El Garhy N, Ali L, El Serafy M, Esmat G, Doss W. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34751609 DOI: 10.1080/14787210.2022.2004117] [Reference Citation Analysis]
38 Zhang M, O'Keefe D, Iwamoto M, Sann K, Kien A, Hang V, Brucker C, Jolivet P, Ly S, Chhit D, Balkan S, Marquardt T, Le Paih M, Dousset JP. High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia. J Viral Hepat 2020;27:886-95. [PMID: 32358826 DOI: 10.1111/jvh.13311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
39 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
40 Khairy RMM, Hmmad SS, Sayed M, Ahmed HA, Esmail MAM. Serum MicroRNAs as predictors for fibrosis progression and response to direct-acting antivirals treatment in hepatitis C virus genotype-4 Egyptian patients. Int J Clin Pract 2021;75:e13954. [PMID: 33345414 DOI: 10.1111/ijcp.13954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Esmat G, Elbaz T, Elsharkawy A, Abdullah M, El Kassas M. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev Anti Infect Ther 2020;18:637-42. [PMID: 32302245 DOI: 10.1080/14787210.2020.1758065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. J Viral Hepat. 2019;26:263-270. [PMID: 30380158 DOI: 10.1111/jvh.13032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
43 Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, Esheba NE, Elnaggar MH, Soliman S, Abd-Elsalam S. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;11:441-445. [PMID: 29628768 DOI: 10.2147/idr.s160593] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
44 Tang L, Kamat M, Shukla A, Vora M, Kalal C, Kottilil S, Shah S. Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. Interdiscip Perspect Infect Dis 2018;2018:9124604. [PMID: 30364048 DOI: 10.1155/2018/9124604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Mostafa A, El-Sayed MH, El Kassas M, Elhamamsy M, Elsisi GH. Safety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From Egypt. Value Health Reg Issues 2019;19:51-8. [PMID: 31002984 DOI: 10.1016/j.vhri.2018.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Abbass S, Kamal E, Salama M, Salman T, Sabry A, Abdel-Razek W, Helmy S, Abdelgwad A, Sakr N, Elgazzar M, Einar M, Farouk M, Saif M, Shehab I, El-Hosieny E, Mansour M, Mahdi D, Tharwa ES, Salah M, Elrouby O, Waked I. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol 2021. [PMID: 34379337 DOI: 10.1002/jmv.27264] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Youssef AA, Magdy N, Hussein LA, El-Kosasy AM. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt. J Chromatogr Sci 2019;57:636-43. [PMID: 31063182 DOI: 10.1093/chromsci/bmz038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
48 El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018;12:1265-1272. [PMID: 29757684 DOI: 10.1080/17474124.2018.1476137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
49 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
50 Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int 2018;12:348-55. [PMID: 29754329 DOI: 10.1007/s12072-018-9868-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
51 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Ismail WA, Yousef AE. Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis. Eur J Gastroenterol Hepatol 2019;31:1025-9. [PMID: 30702448 DOI: 10.1097/MEG.0000000000001370] [Reference Citation Analysis]
53 Merat S; SD1000 Research Team. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis 2020;70:2206-12. [PMID: 31504303 DOI: 10.1093/cid/ciz628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
54 Örmeci N, Gülşen MT, Sezgin O, Aghayeva S, Demir M, Köksal I, Güner R, Erarslan E, Asiller ÖÖ, Balkan A, Yaraş S, Çalışkan Kartal A. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol 2020;31:148-55. [PMID: 32141824 DOI: 10.5152/tjg.2020.19440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Nagaty A, Helmy SH, Abd El-Wahab EW. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Trans R Soc Trop Med Hyg 2020;114:200-12. [PMID: 31722032 DOI: 10.1093/trstmh/trz079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ebid AIM, Ahmed OA, Agwa SH, Abdel-Motaleb SM, Hagag RS. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. Int J Clin Pharm 2020;42:1207-16. [PMID: 32712884 DOI: 10.1007/s11096-020-01085-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Charatcharoenwitthaya P, Wongpaitoon V, Komolmit P, Sukeepaisarnjaroen W, Tangkijvanich P, Piratvisuth T, Sanpajit T, Sutthivana C, Bunchorntavakul C, Sobhonslidsuk A, Chonprasertsuk S, Siripipattanamongkol C, Sethasine S, Tanwandee T; THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. BMC Gastroenterol 2020;20:47. [PMID: 32138687 DOI: 10.1186/s12876-020-01196-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
58 El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, Ezzat S, Tahoon M, Abdelsalam L, Abdelhakam SM, Ali-Eldin Z. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med 2019;10:295-302. [PMID: 34652758 DOI: 10.1007/s41999-019-00167-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]